NDAORALCAPSULE, EXTENDED RELEASE
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
CREXONT (carbidopa and levodopa) by Viatris (2) is dopa decarboxylase inhibitors [moa]. Approved for parkinson disease. First approved in 2024.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CREXONT is an extended-release oral capsule combining carbidopa and levodopa, approved August 2024 by Viatris for Parkinson's disease treatment. It works by inhibiting DOPA decarboxylase, allowing levodopa to reach the brain and replenish dopamine levels in patients with motor dysfunction. This formulation represents a new delivery platform for a classic combination therapy.
Growth15.6 years to LOE
Early-stage commercial launch with growth potential; entry product for brand teams to establish market presence against established carbidopa/levodopa competitors.
Mechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid
Indications (1)
Clinical Trials (1)
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide
Started Mar 2009
52 enrolled
Parkinson Disease
Career Relevance
CREXONT offers early-career entry and mid-career advancement opportunities in a growth-stage neurology product within Viatris' established Parkinson's franchise. Professionals joining now will build the brand foundation in a competitive specialty care landscape with long patent protection and multiple therapeutic areas to leverage.
Worked on CREXONT at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.